The xT CDx is a state-of-the-art Next Generation Sequencing (NGS) diagnostic tool designed to detect genetic alterations in cancer patients. Utilizing a sample from formalin-fixed paraffin-embedded (FFPE) tissue and matched normal samples, it profiles DNA mutations across 648 genes. This comprehensive profile aids in determining personalized treatment paths and identifies patients eligible for specific therapies as detailed in therapeutic product labeling. The xT CDx not only serves as a companion diagnostic but also provides detailed tumor mutation insights crucial for treatment planning.\n\nOne of the key benefits of the xT CDx is its capability to deliver precision in diagnosis and treatment, leveraging genetic data to engage the most suitable therapies for cancer patients. The ability to identify microsatellite instability and pursue thorough tumor mutation profiling sets a new standard in personalized oncology approaches, ensuring that therapies are tailored down to the genetic level. The technology integrates seamlessly with clinical guidelines, enabling healthcare professionals to make informed, data-driven treatments.\n\nIn the landscape of companion diagnostics, the xT CDx stands out, providing wide-ranging genetic information that surpasses conventional diagnostics. Its application ensures that oncologists have access to the most relevant genetic insights, shaping a more predictive and personalized approach to cancer care. Available as a single-site assay from Tempus Labs in Chicago, the xT CDx embodies a leap forward in how cancer biomarker screening informs and enhances clinical decisions.
